Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy.
Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy.
Atherosclerosis. 2020 Mar;297:8-15. doi: 10.1016/j.atherosclerosis.2020.01.026. Epub 2020 Jan 31.
Cholesteryl ester storage disease (CESD) due to LIPA gene mutations is characterized by hepatic steatosis, hypercholesterolemia and hypoalphalipoproteinemia, exposing affected patients to an increased cardiovascular risk. Further insights into the impact of LIPA gene mutations on lipid/lipoprotein metabolism are limited. Aim of the study was to investigate the effect of carrying one or two mutant LIPA alleles on lipoprotein composition and function.
Lipoproteins were isolated from 6 adult CESD patients, 5 relatives carrying one mutant LIPA allele (carriers) and 12 sex/age matched controls. Lipid profile, lipoprotein mass composition and the fatty acid distribution of cholesteryl esters (CEs) were assessed. HDL function was evaluated as the ability to promote nitric oxide release by endothelial cells.
Despite the lipid-lowering therapy, total cholesterol, LDL-cholesterol and triglycerides were increased in CESD patients compared to controls, while HDL-cholesterol was reduced. Carriers also displayed elevated total and LDL-cholesterol. Very low and intermediate density lipoproteins from CESD patients and carriers were enriched in CEs compared to the control ones, with a concomitant reduction of triglycerides. Fatty acid composition of CEs in serum and lipoproteins showed a depletion of linoleate content in CESD patients, due to the reduced LCAT activity. In CESD HDL, fatty acid distribution of CEs was shifted towards saturated ones, if compared to control HDL. The changes in HDL composition did not affect HDL ability to promote nitric oxide release by endothelial cells.
LIPA gene mutations significantly affected plasma levels and lipid composition of lipoproteins, likely contributing to the increased cardiovascular risk of affected patients.
由于 LIPA 基因突变导致的胆固醇酯贮积症(CESD)的特征是肝脂肪变性、高胆固醇血症和低α脂蛋白血症,使受影响的患者面临更高的心血管风险。然而,对于 LIPA 基因突变对脂质/脂蛋白代谢的影响的进一步了解是有限的。本研究的目的是探讨携带一个或两个突变 LIPA 等位基因对脂蛋白组成和功能的影响。
从 6 名成年 CESD 患者、5 名携带一个突变 LIPA 等位基因的亲属(携带者)和 12 名性别/年龄匹配的对照中分离脂蛋白。评估了脂质谱、脂蛋白质量组成和胆固醇酯(CEs)的脂肪酸分布。通过评估内皮细胞中一氧化氮释放的能力来评估 HDL 功能。
尽管进行了降脂治疗,但 CESD 患者的总胆固醇、LDL 胆固醇和甘油三酯仍高于对照组,而 HDL 胆固醇则降低。携带者也表现出总胆固醇和 LDL 胆固醇升高。与对照组相比,CESD 患者和携带者的极低密度和中间密度脂蛋白中 CE 含量增加,同时甘油三酯减少。血清和脂蛋白中 CE 的脂肪酸组成显示 CESD 患者由于 LCAT 活性降低,亚油酸含量减少。与对照 HDL 相比,CESD HDL 中的 CE 脂肪酸分布向饱和脂肪酸转移。HDL 组成的变化并未影响 HDL 促进内皮细胞一氧化氮释放的能力。
LIPA 基因突变显著影响了脂蛋白的血浆水平和脂质组成,可能导致受影响患者的心血管风险增加。